We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

By LabMedica International staff writers
Posted on 26 Jan 2023

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. More...

However, positive blood culture results can be frequently wrong, and about 40% of positive results return a false-positive result owing to contamination. Such false-positive results can cause misdiagnosis of sepsis and expose the patient to unnecessary, prolonged, and harmful broad-spectrum antibiotic treatment and extended length of in-patient hospital stay. This may put the patent at a higher risk for acute kidney injury, Clostridioides difficile infection (CDI), Multidrug-Resistant Organism (MDRO) infections, other hospital-acquired infections (HAI), and significantly high hospital costs. Preventing false-positive results and sepsis misdiagnosis has to begin with reducing blood culture contaminations. Now, a new technology can help reduce blood culture contamination and false-positive test results, thereby preventing the patient from being harmed, and reducing unnecessary and prolonged usage of antibiotics, duration of stay, and hospital expenses.

Magnolia Medical Technologies’ (Seattle, WA, USA) Steripath is the only FDA 510(k)-cleared device that is specifically indicated to reduce blood culture contamination with an FDA-cleared labeling claim for an 83% and 88% reduction in contamination rates. Optimally designed for blood culture contamination prevention, Steripath comes pre-assembled and sterile to actively divert and sequester the initial 1.5-2.0mL of blood, the volume that is known to contain contaminants. Blood cultures are collected through an independent, second flow path, creating a closed vein-to-bottle collection system meant to avoid bypassing diversion.

Magnolia is entering into partnerships with hospitals and healthcare providers in the U.S. to prevent sepsis misdiagnosis by improving the accuracy of blood culture results using Steripath. A recent peer-reviewed study published in a leading medical journal constituted the largest controlled clinical dataset ever documented with zero blood culture contamination events. Importantly, the study demonstrated that it was possible to eliminate blood culture contamination and “get to zero” with the use of Steripath. Another large-scale, peer-reviewed study quantified multiple devastating patient harms associated with blood culture contamination and most significantly, a 74% higher risk of in-hospital patient mortality.

“This study includes one of the largest data sets to date examining and directly quantifying the preventable consequences of blood culture contamination on patient safety and clinical outcomes,” said Greg Bullington, CEO and Co-Founder of Magnolia Medical. “This definitive data adds to the substantial body of evidence that already exists demonstrating that contaminated blood culture results drive avoidable, severely negative outcomes for patients and the healthcare system, including increased costs, inappropriate antibiotic usage that contributes to the rise of multidrug-resistant organisms, increased length of stay, and other preventable adverse events.”

Related Links:
Magnolia Medical Technologies


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Toxoplasma Gondii Test
Toxo IgG ELISA
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: Cord blood proteomics can identify biomarkers of early-onset neonatal sepsis (Photo courtesy of JCI Insight (2025). DOI: 10.1172/jci.insight.193826)

Umbilical Cord Blood Test Can Detect Early Sepsis in Preterm Infants

Diagnosing early onset sepsis (EOS) in preterm infants is particularly difficult due to the lack of specific clinical signs, leading to widespread use of antibiotics while awaiting culture results.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: NGS can detect one tumor cell among a million healthy cells from a simple blood sample (Photo courtesy of Shutterstock)

New Tool Detects Breast Cancer Relapses Five Years in Advance

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.